siRNA therapeutics: insights, challenges, remedies and future prospects

References

• Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5(1):101. doi: 10.1038/s41392-020-0207-x
   PubMed Web of Science ®Google Scholar
• Artiga A, Serrano-Sevilla I, De Matteis L, et al. Current status and future perspectives of gold nanoparticle vectors for siRNA delivery. J Mater Chem B. 2019;7(6):876–896. doi: 10.1039/C8TB02484G
   PubMed Web of Science ®Google Scholar
• Gao H, Cheng R, Santos HA. Nanoparticle‐mediated siRNA delivery systems for cancer therapy. VIEW. 2021;2(3):20200111. doi: 10.1002/VIW.20200111
   Google Scholar
• Lee SH, Kang YY, Jang HE, et al. Current preclinical small interfering RNA (siRNA)-based conjugate systems for RNA therapeutics. Adv Drug Deliv Rev. 2016;104:78–92. doi: 10.1016/j.addr.2015.10.009
   PubMed Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541–555. doi: 10.1038/nrg3763
   PubMed Web of Science ®Google Scholar
• Zhou J, Shum KT, Burnett J, et al. Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals. 2013;6(1):85–107. doi: 10.3390/ph6010085
   Google Scholar
• Palakurthi S, Yellepeddi VK, Vangara KK. Recent trends in cancer drug resistance reversal strategies using nanoparticles. Expert Opin Drug Deliv. 2012 Mar;9(3):287–301. doi: 10.1517/17425247.2012.665365
   PubMed Web of Science ®Google Scholar
• Gilbert W. Origin of life: the RNA world. Nature. 1986;319(6055):618–618. doi: 10.1038/319618a0
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494–498. doi: 10.1038/35078107
   PubMed Web of Science ®Google Scholar
• Hüttenhofer A, Schattner P, Polacek N. Non-coding RNAs: hope or hype? Trends Genet. 2005;21(5):289–297. doi: 10.1016/j.tig.2005.03.007
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811. doi: 10.1038/35888
   PubMed Web of Science ®Google Scholar
• Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science. 1999;286(5441):950–952. doi: 10.1126/science.286.5441.950
   PubMed Web of Science ®Google Scholar
• Khelghati N, Soleimanpour Mokhtarvand J, Mir M, et al. The importance of co-delivery of nanoparticle-siRNA and anticancer agents in cancer therapy. Chem Biol Drug Des. 2021;97(4):997–1015. doi: 10.1111/cbdd.13824
   PubMed Web of Science ®Google Scholar
• Epstein W, Beckwith JR. Regulation of gene expression. Annu Rev Biochem. 1968;37(1):411–436. doi: 10.1146/annurev.bi.37.070168.002211
   Google Scholar
• Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009;457(7228):426–433. doi: 10.1038/nature07758
   PubMed Web of Science ®Google Scholar
• Patil VS, Zhou R, Rana TM. Gene regulation by non-coding RNAs. Crit Rev Biochem Mol Biol. 2014;49(1):16–32. doi: 10.3109/10409238.2013.844092
   PubMed Web of Science ®Google Scholar
• Saraswathy M, Gong S. Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment. Mater Today. 2014;17(6):298–306. doi: 10.1016/j.mattod.2014.05.002
   Web of Science ®Google Scholar
• Cavallaro G, Sardo C, Craparo EF, et al. Polymeric nanoparticles for siRNA delivery: production and applications. Int J Pharm. 2017;525(2):313–333. doi: 10.1016/j.ijpharm.2017.04.008
   PubMedGoogle Scholar
• Daka A, Peer D. RNAi-based nanomedicines for targeted personalized therapy. Adv Drug Deliv Rev. 2012;64(13):1508–1521. doi: 10.1016/j.addr.2012.08.014
   PubMed Web of Science ®Google Scholar
• Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet. 2009;10(2):94–108. doi: 10.1038/nrg2504
   PubMed Web of Science ®Google Scholar
• Zuckerman JE, Davis ME. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov. 2015 Dec;14(12):843–856. doi: 10.1038/nrd4685
   PubMed Web of Science ®Google Scholar
• Gallas A, Alexander A, Davies MC, et al. Chemistry and formulations for siRNA therapeutics. Chem Soc Rev. 2013;42(20):7983–7997. doi: 10.1039/c3cs35520a
   PubMed Web of Science ®Google Scholar
• Sajid MI, Moazzam M, Kato S, et al. Overcoming barriers for siRNA therapeutics: from bench to bedside. Pharmaceuticals (Basel). 2020;13(10):294. doi: 10.3390/ph13100294
   PubMedGoogle Scholar
• Matranga C, Tomari Y, Shin C, et al. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell. 2005;123(4):607–620. doi: 10.1016/j.cell.2005.08.044
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129–138. doi: 10.1038/nrd2742
   PubMed Web of Science ®Google Scholar
• Tieu T, Wei Y, Cifuentes‐Rius A, et al. Overcoming barriers: clinical translation of siRNA nanomedicines. Adv Ther. 2021;4(9):2100108. doi: 10.1002/adtp.202100108
   Google Scholar
• Juliano R, Bauman J, Kang H, et al. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm. 2009;6:686–695. doi: 10.1021/mp900093r
   PubMed Web of Science ®Google Scholar
• Setten RL, Rossi JJ, Han S. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421–446. doi: 10.1038/s41573-019-0017-4
   PubMed Web of Science ®Google Scholar
• Liu Y, Song Z, Zheng N, et al. Systemic siRNA delivery to tumors by cell-penetrating α-helical polypeptide-based metastable nanoparticles. Nanoscale. 2018;10(32):15339–15349. doi: 10.1039/C8NR03976C
   PubMed Web of Science ®Google Scholar
• Mainini F, Eccles MR. Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy. Molecules. 2020;25(11):2692. doi: 10.3390/molecules25112692
   PubMed Web of Science ®Google Scholar
• Tatiparti K, Sau S, Kashaw SK, et al. siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials. 2017;7(4):77. doi: 10.3390/nano7040077
   Web of Science ®Google Scholar
• Li D, Gao C, Kuang M, et al. Nanoparticles as Drug delivery systems of RNAi in cancer therapy. Molecules. 2021;26(8):2380. doi: 10.3390/molecules26082380
   PubMed Web of Science ®Google Scholar
• van de Water FM, Boerman OC, Wouterse AC, et al. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos. 2006;34(8):1393–1397. doi: 10.1124/dmd.106.009555
   PubMed Web of Science ®Google Scholar
• Saw PE, Song EW. siRNA therapeutics: a clinical reality. Sci China Life Sci. 2020;63(4):485–500. doi: 10.1007/s11427-018-9438-y
   PubMed Web of Science ®Google Scholar
• Lorenzer C, Dirin M, Winkler AM, et al. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release. 2015;203:1–15.
   PubMed Web of Science ®Google Scholar
• Dong Y, Siegwart DJ, Anderson DG. Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev. 2019;144:133–147.
   PubMed Web of Science ®Google Scholar
• Narum SM, Le T, Le DP, et al. Passive targeting in nanomedicine: fundamental concepts, body interactions, and clinical potential. Nanopart Biomed App. 2020;37–53. doi: 10.1016/b978-0-12-816662-8.00004-7
   Google Scholar
• Zhou Y, Zhang C, Liang W. Development of RNAi technology for targeted therapy–a track of siRNA based agents to RNAi therapeutics. J Control Release. 2014;193:270–281. doi: 10.1016/j.jconrel.2014.04.044
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhao Y, Zhao X, et al. Enhancing the therapeutic delivery of oligonucleotides by chemical modification and nanoparticle encapsulation. Molecules. 2017;22(10):1724. doi: 10.3390/molecules22101724
   PubMed Web of Science ®Google Scholar
• Salmaso S, Caliceti P. Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv. 2013;2013:374252. doi: 10.1155/2013/374252
   PubMedGoogle Scholar
• Wang J, Lu Z, Wientjes MG, et al. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010;12(4):492–503. doi: 10.1208/s12248-010-9210-4
   PubMed Web of Science ®Google Scholar
• Young SW, Stenzel M, Yang JL. Nanoparticle-siRNA: a potential cancer therapy? Crit Rev Oncol Hematol. 2016;98:159–169. doi: 10.1016/j.critrevonc.2015.10.015
   PubMed Web of Science ®Google Scholar
• Babu A, Muralidharan R, Amreddy N, et al. Nanoparticles for siRNA-Based gene silencing in tumor therapy. IEEE Trans NanoBiosci. 2016;15(8):849–863. doi: 10.1109/TNB.2016.2621730
   PubMed Web of Science ®Google Scholar
• Williford JM, Wu J, Ren Y, et al. Recent advances in nanoparticle-mediated siRNA delivery. Annu Rev Biomed Eng. 2014;16:347–370. doi: 10.1146/annurev-bioeng-071813-105119
   PubMed Web of Science ®Google Scholar
• Miele E, Spinelli GP, Miele E, et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine. 2012;7:3637–3657. doi: 10.2147/IJN.S23696
   PubMed Web of Science ®Google Scholar
• Subhan MA, Torchilin VP. siRNA based drug design, quality, delivery and clinical translation. Nanomedicine. 2020;29:102239. doi: 10.1016/j.nano.2020.102239
   PubMed Web of Science ®Google Scholar
• Tomalia DA. In quest of a systematic framework for unifying and defining nanoscience. J Nanopart Res. 2009;11(6):1251–1310. doi: 10.1007/s11051-009-9632-z
   PubMed Web of Science ®Google Scholar
• Bartlett DW, Davis ME. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006;34(1):322–333. doi: 10.1093/nar/gkj439
   PubMed Web of Science ®Google Scholar
• Sheikhi F, Fischer W, Haag R. Dendritic and lipid-based carriers for gene/siRNA delivery (a review). Curr Opin Solid State And Mater Sci. 2012;16(6):310–322. doi: 10.1016/j.cossms.2013.01.003
   Web of Science ®Google Scholar
• Seth PP, Tanowitz M, Bennett CF. Selective tissue targeting of synthetic nucleic acid drugs. J Clin Invest. 2019;129(3):915–925. doi: 10.1172/JCI125228
   PubMed Web of Science ®Google Scholar
• Zhang X, Goel V, Robbie GJ. Pharmacokinetics of Patisiran, the first approved RNA interference therapy in patients with Hereditary transthyretin-mediated amyloidosis. J Clin Pharmacol. 2020;60(5):573–585. doi: 10.1002/jcph.1553
   PubMed Web of Science ®Google Scholar
• Crooke ST, Witztum JL, Bennett CF, et al. RNA-Targeted therapeutics. Cell Metab. 2018;27(4):714–739. doi: 10.1016/j.cmet.2018.03.004
   PubMed Web of Science ®Google Scholar
• Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2017;35(3):222–229. doi: 10.1038/nbt.3802
   PubMed Web of Science ®Google Scholar
• Mo RH, Zaro JL, Ou JH, et al. Effects of lipofectamine 2000/siRNA complexes on autophagy in hepatoma cells. Mol Biotechnol. 2012;51(1):1–8. doi: 10.1007/s12033-011-9422-6
   PubMed Web of Science ®Google Scholar
• Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008;26(4):431–442. doi: 10.1038/nbt1396
   PubMed Web of Science ®Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, et al. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12. doi: 10.3390/pharmaceutics9020012
   PubMed Web of Science ®Google Scholar
• Gote V, Pal D. Octreotide-targeted Lcn2 siRNA PEGylated liposomes as a treatment for metastatic breast cancer. Bioeng. 2021;8(4):44. doi: 10.3390/bioengineering8040044
   PubMedGoogle Scholar
• Rossi JJ. RNAi therapeutics: SNALPing siRnas in vivo. Gene Ther. 2006;13(7):583–584. doi: 10.1038/sj.gt.3302661
   PubMed Web of Science ®Google Scholar
• Gallarate M, Battaglia L, Peira E, et al. Peptide-loaded solid lipid nanoparticles prepared through coacervation technique. Int J Chem Eng. 2011;2011(7):1–6. doi: 10.1155/2011/132435
   Google Scholar
• Sarisozen C, Salzano G, Torchilin VP. Lipid-based siRNA delivery systems: challenges, promises and solutions along the long journey. Curr Pharm Biotechnol. 2016;17(8):728–740. doi: 10.2174/1389201017666160401145319
   PubMed Web of Science ®Google Scholar
• Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRnas. Nat Biotechnol. 2005;23(8):1002–1007. doi: 10.1038/nbt1122
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006 May 4;441(7089):111–114. doi: 10.1038/nature04688
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375(9729):1896–1905. doi: 10.1016/S0140-6736(10)60357-1
   PubMed Web of Science ®Google Scholar
• Coutinho MF, Santos JI, Mendonça LS, et al. Lysosomal storage disease-associated neuropathy: targeting stable nucleic acid lipid particle (SNALP)-formulated siRnas to the brain as a therapeutic approach. Int J Mol Sci. 2020;21(16):5732. doi: 10.3390/ijms21165732
   PubMed Web of Science ®Google Scholar
• Mills KA, Quinn JM, Roach ST, et al. p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts. Sci Rep. 2019;9(1):4762. doi: 10.1038/s41598-019-41122-3
   PubMedGoogle Scholar
• Love KT, Mahon KP, Levins CG, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A. 2010;107(5):1864–1869. doi: 10.1073/pnas.0910603106
   PubMed Web of Science ®Google Scholar
• Khare P, Dave KM, Kamte YS, et al. Development of lipidoid nanoparticles for siRNA delivery to neural cells. AAPS J. 2021;24(1):8. doi: 10.1208/s12248-021-00653-2
   PubMed Web of Science ®Google Scholar
• Yu YH, Kim E, Park DE, et al. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur J Pharm Biopharm. 2012;80(2):268–273. doi: 10.1016/j.ejpb.2011.11.002
   PubMed Web of Science ®Google Scholar
• Kong WH, Park K, Lee MY, et al. Cationic solid lipid nanoparticles derived from apolipoprotein-free LDLs for target specific systemic treatment of liver fibrosis. Biomaterials. 2013;34(2):542–551. doi: 10.1016/j.biomaterials.2012.09.067
   PubMed Web of Science ®Google Scholar
• O’Mary HL, Hanafy MS, Aldayel AM, et al. Effect of the ratio of betamethasone to TNF-α siRNA coencapsulated in solid lipid nanoparticles on the Acute proinflammatory activity of the nanoparticles. Mol Pharm. 2019;16(11):4496–4506. doi: 10.1021/acs.molpharmaceut.9b00629
   PubMedGoogle Scholar
• Chen C, Dong C, Shi S. Nanoparticle‐mediated siRNA delivery and multifunctional modification strategies for effective cancer therapy. Adv Mater Technol. 2021;6(10):2001236. doi: 10.1002/admt.202001236
   Web of Science ®Google Scholar
• Gandhi NS, Tekade RK, Chougule MB. Nanocarrier mediated delivery of siRna/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release. 2014;194:238–256. doi: 10.1016/j.jconrel.2014.09.001
   PubMed Web of Science ®Google Scholar
• Ho W, Zhang XQ, Xu X. Biomaterials in siRNA delivery: a comprehensive review. Adv Healthc Mater. 2016;5(21):2715–2731. doi: 10.1002/adhm.201600418
   PubMed Web of Science ®Google Scholar
• Akhtar S, Benter IF. Nonviral delivery of synthetic siRnas in vivo. J Clin Invest. 2007;117(12):3623–3632. doi: 10.1172/JCI33494
   PubMed Web of Science ®Google Scholar
• Winkler J. Oligonucleotide conjugates for therapeutic applications, Ther. Deliv. 2013;4:791–809. doi: 10.4155/tde.13.47
   PubMedGoogle Scholar
• Oishi M, Nagasaki Y, Itaka K, et al. Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J Am Chem Soc. 2005;127(6):1624–1625. doi: 10.1021/ja044941d
   PubMed Web of Science ®Google Scholar
• Khvalevsky EZ, Gabai R, Rachmut IH, et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci. 2013;110(51):20723–20728. doi: 10.1073/pnas.1314307110
   PubMed Web of Science ®Google Scholar
• Tai W. Current aspects of siRNA bioconjugate for in vitro and in vivo delivery. Molecules. 2019;24(12):2211. doi: 10.3390/molecules24122211
   PubMed Web of Science ®Google Scholar
• Yuan X, Naguib S, Wu Z. Recent advances of siRNA delivery by nanoparticles. Expert Opin Drug Deliv. 2011;8(4):521–536. doi: 10.1517/17425247.2011.559223
   PubMed Web of Science ®Google Scholar
• Ragelle H, Vandermeulen G, Préat V. Chitosan-based siRNA delivery systems. J Control Release. 2013;172(1):207–218. doi: 10.1016/j.jconrel.2013.08.005
   PubMed Web of Science ®Google Scholar
• Shajari N, Mansoori B, Davudian S, et al. Overcoming the challenges of siRNA delivery: nanoparticle strategies. Curr Drug Deliv. 2017;14(1):36–46. doi: 10.2174/1567201813666160816105408
   PubMed Web of Science ®Google Scholar
• Howard KA, Paludan SR, Behlke MA, et al. Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther. 2009;17(1):162–168. doi: 10.1038/mt.2008.220
   PubMed Web of Science ®Google Scholar
• Salehi Khesht AM, Karpisheh V, Sahami Gilan P, et al. Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo. Int j biol macromol. 2021;186:849–863. doi: 10.1016/j.ijbiomac.2021.07.034
   PubMed Web of Science ®Google Scholar
• Chaturvedi K, Ganguly K, Kulkarni AR, et al. Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review. Expert Opin Drug Deliv. 2011;8(11):1455–1468. doi: 10.1517/17425247.2011.610790
   PubMed Web of Science ®Google Scholar
• Heidel JD, Yu Z, Liu JY, et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A. 2007;104(14):5715–5721. doi: 10.1073/pnas.0701458104
   PubMed Web of Science ®Google Scholar
• Mendonça MCP, Cronin MF, Cryan JF, et al. Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model. Eur J Pharm Biopharm. 2021;169:309–318. doi: 10.1016/j.ejpb.2021.11.003
   PubMed Web of Science ®Google Scholar
• Mousazadeh H, Bonabi E, Zarghami N. Stimulus-responsive drug/gene delivery system based on polyethylenimine cyclodextrin nanoparticles for potential cancer therapy. Carbohydr Polym. 2022;276:118747. doi: 10.1016/j.carbpol.2021.118747
   PubMed Web of Science ®Google Scholar
• Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 2009;61(10):850–862. doi: 10.1016/j.addr.2009.04.018
   PubMed Web of Science ®Google Scholar
• Takei Y. siRNA-Based Drug targeting human Bcl-xL against cancers. Methods Mol Biol. 2019;1974:31–40.
   PubMedGoogle Scholar
• Singha K, Namgung R, Kim WJ. Polymers in small-interfering RNA delivery. Nucleic Acid Ther. 2011;21(3):133–147. doi: 10.1089/nat.2011.0293
   PubMed Web of Science ®Google Scholar
• Tan PH, Yang LC, Shih HC, et al. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Thera. 2004;12(1):59–66. doi: 10.1038/sj.gt.3302376
   Web of Science ®Google Scholar
• Urban-Klein B, Werth S, Abuharbeid S, et al. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2005;12(5):461–466. doi: 10.1038/sj.gt.3302425
   PubMed Web of Science ®Google Scholar
• Schiffelers M, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004;32(19):e149–e149. doi: 10.1093/nar/gnh140
   PubMed Web of Science ®Google Scholar
• Yang S, Wang D, Zhang X, et al. cRGD peptide-conjugated polyethylenimine-based lipid nanoparticle for intracellular delivery of siRNA in hepatocarcinoma therapy. Drug Deliv. 2021;28(1):995–1006. doi: 10.1080/10717544.2021.1928794
   PubMed Web of Science ®Google Scholar
• Wu ZW, Chien CT, Liu CY, et al. Recent progress in copolymer-mediated siRNA delivery. J Drug Target. 2012;20(7):551–560. doi: 10.3109/1061186X.2012.699057
   PubMed Web of Science ®Google Scholar
• Katas H, Cevher E, Alpar HO. Preparation of polyethyleneimine incorporated poly(D,L-lactide-co-glycolide) nanoparticles by spontaneous emulsion diffusion method for small interfering RNA delivery. Int J Pharm. 2009;369(1–2):144–154. doi: 10.1016/j.ijpharm.2008.10.012
   PubMed Web of Science ®Google Scholar
• Woodrow KA, Cu Y, Booth CJ, et al. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater. 2009;8(6):526–533. doi: 10.1038/nmat2444
   PubMed Web of Science ®Google Scholar
• Jensen DM, Cun D, Maltesen MJ, et al. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J Control Release. 2010;142(1):138–145. doi: 10.1016/j.jconrel.2009.10.010
   PubMed Web of Science ®Google Scholar
• Pho-Iam T, Punnakitikashem P, Somboonyosdech C, et al. PLGA nanoparticles containing α-fetoprotein siRNA induce apoptosis and enhance the cytotoxic effects of doxorubicin in human liver cancer cell line. Biochem Biophys Res Commun. 2021;553:191–197. doi: 10.1016/j.bbrc.2021.03.086
   PubMed Web of Science ®Google Scholar
• Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today. 2010;15(5–6):171–185. doi: 10.1016/j.drudis.2010.01.009
   PubMed Web of Science ®Google Scholar
• Dwivedi P, Tekade RK, Jain NK. Nanoparticulate carrier mediated intranasal delivery of insulin for the restoration of memory signaling in alzheimer’s disease. Curr Nanosci. 2013;9(1):46–55. doi: 10.2174/1573413711309010010
   Web of Science ®Google Scholar
• Alper J. Rising chemical ‘stars’ could play many roles. Science. 1991;251(5001):1562–1564. doi: 10.1126/science.2011736
   PubMed Web of Science ®Google Scholar
• Lee JH, Cha KE, Kim MS, et al. Nanosized polyamidoamine (PAMAM) dendrimer-induced apoptosis mediated by mitochondrial dysfunction. Toxicol Lett. 2009;190(2):202–207. doi: 10.1016/j.toxlet.2009.07.018
   PubMed Web of Science ®Google Scholar
• Jain A, Mahira S, Majoral JP, et al. Dendrimer mediated targeting of siRNA against polo-like kinase for the treatment of triple negative breast cancer. J Biomed Mater Res A. 2019;107(9):1933–1944. doi: 10.1002/jbm.a.36701
   PubMed Web of Science ®Google Scholar
• Daniel MC, Astruc D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev. 2004;104(1):293–346.
   PubMed Web of Science ®Google Scholar
• Zhao J, Feng SS. Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents. Nanomedicine (Lond). 2015;10(14):2199–2228. doi: 10.2217/nnm.15.61
   PubMed Web of Science ®Google Scholar
• Jensen SA, Day ES, Ko CH, et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med. 2013;5(209). doi: 10.1126/scitranslmed.3006839
   PubMed Web of Science ®Google Scholar
• Cutler JI, Auyeung E, Mirkin CA. Spherical nucleic acids. J Am Chem Soc. 2012;134(3):1376–1391. doi: 10.1021/ja209351u
   PubMed Web of Science ®Google Scholar
• Zhuang M, Jiang S, Gu A, et al. Radiosensitizing effect of gold nanoparticle loaded with small interfering RNA-SP1 on lung cancer. Transl Oncol. 2021;14(12):101210. doi: 10.1016/j.tranon.2021.101210
   PubMed Web of Science ®Google Scholar
• Ku SH, Kim K, Choi K, et al. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy. Adv Healthc Mater. 2014;3(8):1182–1193. doi: 10.1002/adhm.201300607
   PubMed Web of Science ®Google Scholar
• Nosrati H, Salehiabar M, Fridoni M, et al. New insight about biocompatibility and biodegradability of iron oxide magnetic nanoparticles: stereological and in vivo MRI monitor. Sci Rep. 2019;9(1):7173. doi: 10.1038/s41598-019-43650-4
   PubMedGoogle Scholar
• Yang Z, Duan J, Wang J, et al. Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy. Int J Nanomedicine. 2018;13:1851–1865. doi: 10.2147/IJN.S155537
   PubMed Web of Science ®Google Scholar
• Slowing I, Viveroescoto L, Wu C, et al. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60(11):1278–1288. doi: 10.1016/j.addr.2008.03.012
   PubMed Web of Science ®Google Scholar
• Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater. 2012;24(12):1504–1534. doi: 10.1002/adma.201104763
   PubMed Web of Science ®Google Scholar
• Ovejero Paredes K, Díaz-García D, García-Almodóvar V, et al. Multifunctional silica-based nanoparticles with controlled release of organotin metallodrug for targeted theranosis of breast cancer. Cancers (Basel). 2020;12(1):187. doi: 10.3390/cancers12010187
   PubMed Web of Science ®Google Scholar
• Li X, Xie QR, Zhang J, et al. The packaging of siRNA within the mesoporous structure of silica nanoparticles. Biomaterials. 2011;32(35):9546–9556. doi: 10.1016/j.biomaterials.2011.08.068
   PubMed Web of Science ®Google Scholar
• Heidari R, Khosravian P, Mirzaei SA, et al. siRNA delivery using intelligent chitosan-capped mesoporous silica nanoparticles for overcoming multidrug resistance in malignant carcinoma cells. Sci Rep. 2021;11(1). doi: 10.1038/s41598-021-00085-0
   Web of Science ®Google Scholar
• Tieu T, Alba M, Elnathan R, et al. Theranostics: advances in porous silicon-based nanomaterials for diagnostic and therapeutic applications (Adv. Therap. 1/2019). Adv Therap. 2019;2(1):1970001. doi: 10.1002/adtp.201970001
   Google Scholar
• Joo J, Kwon EJ, Kang J, et al. Porous silicon–graphene oxide core–shell nanoparticles for targeted delivery of siRNA to the injured brain. Nanoscale Horiz. 2016;1(5):407–414. doi: 10.1039/C6NH00082G
   PubMed Web of Science ®Google Scholar
• Tieu T, Wojnilowicz M, Huda P, et al. Nanobody-displaying porous silicon nanoparticles for the co-delivery of siRNA and doxorubicin. Biomater Sci. 2021;9(1):133–147. doi: 10.1039/D0BM01335H
   PubMed Web of Science ®Google Scholar
• Hong G, Diao S, Antaris AL, et al. Carbon nanomaterials for biological imaging and nanomedicinal therapy. Chem Rev. 2015;115(19):10816–10906. doi: 10.1021/acs.chemrev.5b00008
   PubMed Web of Science ®Google Scholar
• Yang Y, Li J, Liu F, et al. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol Ther. 2012;20(3):609–615. doi: 10.1038/mt.2011.270
   PubMed Web of Science ®Google Scholar
• Bates K, Kostarelos K. Carbon nanotubes as vectors for gene therapy: past achievements, present challenges and future goals. Adv Drug Deliv Rev. 2013;65(15):2023–2033. doi: 10.1016/j.addr.2013.10.003
   PubMed Web of Science ®Google Scholar
• Kofoed Andersen C, Khatri S, Hansen J, et al. Carbon nanotubes-Potent carriers for targeted Drug delivery in Rheumatoid arthritis. Pharmaceutics. 2021;13(4):453. doi: 10.3390/pharmaceutics13040453
   PubMed Web of Science ®Google Scholar
• Draz MS, Fang BA, Zhang P, et al. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics. 2014 Jun 11;4(9):872–892. doi: 10.7150/thno.9404
   PubMed Web of Science ®Google Scholar
• Yang YY, Zhang W, Liu H, et al. Cell-penetrating peptide-modified graphene oxide nanoparticles loaded with Rictor siRNA for the treatment of triple-negative breast cancer. Drug Des Devel Ther. 2021;15:4961–4972. doi: 10.2147/DDDT.S330059
   PubMedGoogle Scholar
• Ramasamy T, Munusamy S, Ruttala HB, et al. Smart nanocarriers for the delivery of nucleic acid‐based therapeutics: a comprehensive review. Biotechnol J. 2020;16(2):1900408. doi: 10.1002/biot.201900408
   Web of Science ®Google Scholar
• Suma T, Miyata K, Anraku Y, et al. Smart multilayered assembly for biocompatible siRNA delivery featuring dissolvable silica, endosome-disrupting polycation, and detachable PEG. ACS Nano. 2012;6(8):6693–6705. doi: 10.1021/nn301164a
   PubMed Web of Science ®Google Scholar
• Pittella F, Zhang M, Lee Y, et al. Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity. Biomaterials. 2011;32(11):3106–3114. doi: 10.1016/j.biomaterials.2010.12.057
   PubMed Web of Science ®Google Scholar
• Kakizawa Y, Furukawa S, Ishii A, et al. Organic-inorganic hybrid-nanocarrier of siRNA constructing through the self-assembly of calcium phosphate and PEG-based block aniomer. J Control Release. 2006;111(3):368–370. doi: 10.1016/j.jconrel.2006.01.004
   PubMed Web of Science ®Google Scholar
• Li J, Chen YC, Tseng YC, et al. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release. 2010;142(3):416–421. doi: 10.1016/j.jconrel.2009.11.008
   PubMed Web of Science ®Google Scholar
• Zhang M, Ishii A, Nishiyama N, et al. Pegylated calcium phosphate nanocomposites as Smart environment-sensitive carriers for siRNA delivery. Adv Mater. 2009;21(34):3520–3525. doi: 10.1002/adma.200800448
   Web of Science ®Google Scholar
• Kara G, Parlar A, Cakmak MC, et al. Silencing of survivin and cyclin B1 through siRNA-loaded arginine modified calcium phosphate nanoparticles for non-small-cell lung cancer therapy. Colloids Surf B. 2020;196:111340. doi: 10.1016/j.colsurfb.2020.111340
   PubMed Web of Science ®Google Scholar
• Derfus AM, Chen AA, Min DH, et al. Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem. 2007;18(5):1391–1396. doi: 10.1021/bc060367e
   PubMed Web of Science ®Google Scholar
• Kim MW, Jeong HY, Kang SJ, et al. Anti-EGF receptor aptamer-guided co-delivery of anti-cancer siRnas and quantum dots for Theranostics of triple-negative breast cancer. Theranostics. 2019;9(3):837–852. doi: 10.7150/thno.30228
   PubMed Web of Science ®Google Scholar
• Liu D, Huxford RC, Lin W. Phosphorescent nanoscale coordination polymers as contrast agents for optical imaging. Angew Chem Int Ed Engl. 2011;50(16):3696–3700. doi: 10.1002/anie.201008277
   PubMed Web of Science ®Google Scholar
• Zhang X, Liang T, Ma Q. Layer-by-layer assembled nano-drug delivery systems for cancer treatment. Drug Deliv. 2021 Dec;28(1):655–669. doi: 10.1080/10717544.2021.1905748
   PubMed Web of Science ®Google Scholar
• Muthu MS, Leong DT, Mei L, et al. Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics. 2014;4(6):660–677. doi: 10.7150/thno.8698
   PubMed Web of Science ®Google Scholar
• James SL. Metal-organic frameworks. Chem Soc Rev. 2003;32(5):276. doi: 10.1039/b200393g
   PubMed Web of Science ®Google Scholar
• Horcajada P, Serre C, Vallet-Regí M, et al. Metal-organic frameworks as efficient materials for drug delivery. Angew Chem Int Ed Engl. 2006;45(36):5974–5978. doi: 10.1002/anie.200601878
   PubMed Web of Science ®Google Scholar
• Wang Z, Cohen SM. Postsynthetic modification of metal–organic frameworks. Chem Soc Rev. 2010;38(5):1315. doi: 10.1039/b802258p
   Web of Science ®Google Scholar
• Furukawa H, Ko N, Go YB, et al. Ultrahigh porosity in metal-organic frameworks. Science. 2010;329(5990):424–428. doi: 10.1126/science.1192160
   PubMed Web of Science ®Google Scholar
• He C, Lu K, Liu D, et al. Nanoscale metal-organic frameworks for the co-delivery of cisplatin and pooled siRnas to enhance therapeutic efficacy in drug-resistant ovarian cancer cells. J Am Chem Soc. 2014;136(14):5181–5184. doi: 10.1021/ja4098862
   PubMed Web of Science ®Google Scholar
• Baran-Rachwalska P, Torabi-Pour N, Sutera FM, et al. Topical siRNA delivery to the cornea and anterior eye by hybrid silicon-lipid nanoparticles. J Control Release. 2020;326:192–202. doi: 10.1016/j.jconrel.2020.07.004
   PubMed Web of Science ®Google Scholar
• Cristofolini T, Dalmina M, Sierra JA, et al. Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells. Mater Sci Eng C. 2020;109:110555. doi: 10.1016/j.msec.2019.110555
   PubMed Web of Science ®Google Scholar
• Xiao D, Li Y, Tian T, et al. Tetrahedral framework nucleic acids loaded with aptamer AS1411 for siRNA delivery and gene silencing in malignant melanoma. ACS Appl Mater Inter. 2021;13(5):6109–6118. doi: 10.1021/acsami.0c23005
   PubMed Web of Science ®Google Scholar
• Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci. 2010;123(Pt 8):1183–1189. doi: 10.1242/jcs.066399
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, Aggarwal P, Hall JB, et al. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008;5(4):487–495. doi: 10.1021/mp800032f
   PubMed Web of Science ®Google Scholar
• Iyer AK, Khaled G, Fang J, et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11(17–18):812–818. doi: 10.1016/j.drudis.2006.07.005
   PubMed Web of Science ®Google Scholar
• Merritt WM, Lin YG, Spannuth WA, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008;100(5):359–372. doi: 10.1093/jnci/djn024
   PubMed Web of Science ®Google Scholar
• Adams D, Coelho T, Obici L, et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology. 2015;85(8):675–682. doi: 10.1212/WNL.0000000000001870
   PubMed Web of Science ®Google Scholar
• Balwani M, Sardh E, Ventura P, et al. Phase 3 trial of RNAi therapeutic Givosiran for Acute intermittent porphyria. N Engl J Med. 2020;382(24):2289–2301. doi: 10.1056/NEJMoa1913147
   PubMed Web of Science ®Google Scholar
• Bawa R. Handbook of clinical nanomedicine : law, business, regulation, safety and risk. Singapore: Pan Stanford Publishing; 2016. doi: 10.1201/b19910
   Google Scholar
• Kelly B. Nanomedicines: regulatory challenges and risks ahead. Regul Aff Pharma. 2010;10:4–17.
   Google Scholar
• Soares S, Sousa J, Pais A, et al. Nanomedicine: principles, properties, and regulatory issues. Front Chem. 2018;6:360. doi: 10.3389/fchem.2018.00360
   PubMed Web of Science ®Google Scholar
• Edmondson R, Broglie JJ, Adcock AF, et al. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12(4):207–218. doi: 10.1089/adt.2014.573
   PubMed Web of Science ®Google Scholar
• Sharma HS, Hussain S, Schlager J, et al. Influence of nanoparticles on blood-brain barrier permeability and brain edema formation in rats. Acta Neurochir Suppl. 2010;106:359–364.
   PubMedGoogle Scholar
• Limaye V, Fortwengel G, Limaye D. Regulatory roadmap for nanotechnology based medicines. Int J Drug Regul Aff. 2018;2(4):33–41. doi: 10.22270/ijdra.v2i4.151
   Google Scholar
• Hattab D, Gazzali AM, Bakhtiar A. Clinical advances of siRNA-Based nanotherapeutics for cancer treatment. Pharmaceutics. 2021;13(7):1009. doi: 10.3390/pharmaceutics13071009
   PubMed Web of Science ®Google Scholar